PGCM
OCUL icon

Prescott Group Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Prescott Group Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-313,000
Closed -$3.8M – 283
2025
Q4 		$3.8M Buy
+313,000
New +$3.8M 0.35% 76
2016
Q3 		– Sell
-353,464
Closed -$1.75M – 150
2016
Q2 		$1.75M Buy
+353,464
New +$3.5M 0.42% 58

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Prescott Group Capital Management's OCUL Position: Q1 2026 in Review

Prescott Group Capital Management sold out of Ocular Therapeutix (OCUL) in Q1 2026, closing a stake of 313,000 shares — an estimated $3.8M sold.

Prescott Group Capital Management first reported a position in OCUL in Q2 2016 and held it in 2 quarters. The position peaked at $3.8M in Q4 2025. 271 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Prescott Group Capital Management reported no remaining Ocular Therapeutix position as of Q1 2026 after selling out during the quarter.
  • Prescott Group Capital Management sold 313,000 Ocular Therapeutix shares in Q1 2026, an estimated $3.8M.
  • Prescott Group Capital Management first reported a position in Ocular Therapeutix in Q2 2016 and held it in 2 quarters.
  • Prescott Group Capital Management's Ocular Therapeutix position peaked at $3.8M in Q4 2025.
  • 271 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Prescott Group Capital Management's 13F filing for Q1 2026, filed 7 May 2026.